

P1 1114401

RECEIVED

19 JAN 2004

WIPO

PCT

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

January 14, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/427,514

FILING DATE: November 19, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/35051

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS



*M. Sias*  
M. SIAS  
Certifying Officer

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

11-20-04 042514.111917  
Modified PTO/SH/16 (6-95)  
Approved for use through 04/11/98. OMB 0651-0037  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 CFR 1.53 (c)


Docket Number	P-16031	Type a plus sign (+) inside this box ->	+
---------------	---------	---	---

INVENTOR(s)/APPLICANT(s)			
LAST NAME	FIRST NAME	MIDDLE NAME	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
DETKE	MICHAEL	JOSEPH	CARMEL, INDIANA

**TITLE OF THE INVENTION (280 characters max)**

**TREATMENT OF GASTROINTESTINAL DISORDERS WITH DULOXETINE**

**CORRESPONDENCE ADDRESS**

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288		 <b>25885</b> PATENT TRADEMARK OFFICE			
STATE	IN	ZIP CODE	46206-6288	COUNTRY	USA

**ENCLOSED APPLICATION PARTS (check all that apply)**

<input checked="" type="checkbox"/> Specification	Number of pages	9	<input type="checkbox"/> Small Entity Statement
<input type="checkbox"/> Drawing(s)	Number of Sheets		<input type="checkbox"/> Other (Specify) <span></span>


**METHOD OF PAYMENT (check one)**

<input type="checkbox"/> A check or money order is enclosed to cover the Provisional filing fees	PROVISIONAL FILING FEE AMOUNT (\$)	\$160.00
<input checked="" type="checkbox"/> The Assistant Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number: 05-0840		

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,  
SIGNATURE 

Date 11 / 19 / 02

TYPED or PRINTED NAME ARVIE J. ANDERSON


REGISTRATION NO. (if appropriate) 45,263

☐ Additional inventors are being named on separately numbered sheets attached hereto

**PROVISIONAL APPLICATION FOR PATENT FILING ONLY**

"Express Mail" mailing label number EL 832954/55 US Date of Deposit Nov. 19, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Arlington, VA, 22202.

Printed Name	Signature
<u>Queen Thomas</u>	

**TREATMENT OF GASTROINTESTINAL DISORDERS  
WITH DULOXETINE**

5           The present invention belongs to the fields of medicinal and pharmaceutical chemistry, and provides a new method of treating gastrointestinal disorders by administration of duloxetine.

10           For some years, it has been recognized that the chemistry of serotonin and norepinephrine are extremely important in neurological processes, and pharmacologists and medical researchers have been very actively studying the mechanisms of those neurotransmitters in the brain. Concomitantly, the synthesis and study of pharmaceuticals which affect serotonin and norepinephrine processes in the brain are of great interest and are also being intensively studied, both by  
15           pharmaceutical chemists and by medical researchers as well.

          Duloxetine inhibits the reuptake of both serotonin and norepinephrine, and is now in clinical trials as an antidepressant drug, and also for the treatment of urinary incontinence. The present invention provides the use of duloxetine for an additional  
20           important purpose, the treatment of gastrointestinal disorders.

          Commonly encountered gastrointestinal disorders include inflammatory bowel disorders (IBD) and functional bowel disorders (FBD), including dyspepsia. These GI disorders include a wide range of disease states that are currently only moderately  
25           controlled, including Crohn's disease, ileitis, ischemic bowel disease, and ulcerative colitis, as well as IBD, the irritable bowel syndrome, dyspepsia, and gastro-esophageal reflux for FBD, and other forms of visceral pain.

30

"Express Mail" mailing label number EL 832954155 US Date of Deposit Nov. 19, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

35

Quinn Thomas  
Printed Name

Quinn Thomas  
Signature

P-16031

-2-

The present invention provides a method of treating a gastrointestinal disorder in a patient comprising administering to the patient an effective amount of duloxetine.

Duloxetine is N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine. It is usually administered as the (+) enantiomer, and as the hydrochloride salt. It was first taught by U.S. Patent 4,956,388, which teaches the synthesis of the compound as well as its high potency as an uptake inhibitor of both serotonin and norepinephrine. The word "duloxetine" will be used here to refer to any acid addition salt or the free base of the molecule, as well as to either an enantiomer or the racemate. It is to be understood, however, that the (+) enantiomer is preferred.

The most preferred dose of duloxetine for the treatment of a given patient with any particular gastrointestinal disorder will vary, depending on the characteristics of the patient, as all clinicians and medical doctors are aware. Factors such as other diseases from which the patient suffers, the patient's age and size, and other medications which the patient may be using will have an effect on the duloxetine dose and will be taken into account. In general, however, the daily dose of duloxetine is from about 1 to about 120 mg. The most preferred dose range is between 60 mg QD and 80 mg QD.

Duloxetine is orally available and presently is orally administered, in the form of a tablet or a capsule full of enteric coated granules. Oral administration in such forms is preferred in the practice of the present invention. However, other routes of administration are also practical and may be preferred in certain cases. For example, transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine. Sustained release formulations, oral or percutaneous, may be prepared, but are not preferred because duloxetine is quite effective when administered once daily and there is little benefit from the additional effort of preparing the sustained action product.

30

In general, the formulation of duloxetine for use in the present invention follows the methods used in formulating duloxetine for other purposes, and indeed

P-16031

-3-

methods usual in pharmaceutical science are appropriate. However, a preferred formulation of duloxetine comprises enteric pellets, or granules, of which a number are charged in a gelatin capsule. The duloxetine enteric pellet formulation is described in U.S. Patent No. 5,508,276.

---

5

The patient to be benefited by practice of the present invention is a patient having one or more of the gastrointestinal disorders discussed below. Diagnosis of these disorders, or the identification of a patient at risk of one or more of them, is to be made by a physician. It is presently believed that duloxetine's potency in inhibiting the uptake of serotonin and norepinephrine is the mechanism by which it benefits such patients, by alleviating the effects of the disorder from which the patient suffers, or even eliminating the disorder completely.

10

The disorders which are treated or prevented in the practice of the present invention may be described as follows:

15

inflammatory bowel disorders (IBD),  
functional bowel disorders (FBD),  
dyspepsia,  
crohn's disease,  
ileitis,  
ischemic bowel disease,  
ulcerative colitis,  
irritable bowel syndrome, and  
gastroesophageal reflux for FBD.

20

25

One such type of patient who would benefit from this invention would be a patient suffering from IBS. Such a patient would have symptoms characterized by 'ROME II Criteria'. See practitioner, 217:276-280 (1976). Symptoms include but are not limited to intermittent diarrhea, discomfort, abdominal pain and/or constipation or bloating. Upon administration of duloxetine a patient will experience alleviation of symptoms associated with IBS.

30

P-16031

-4-

As used herein the term "effective amount" refers to the amount or dose of the compound, upon single or multiple dose administration to the patient, which provides the desired effect in the patient under diagnosis or treatment.

---

5           An effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount or dose of compound administered, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and  
10   general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances. For example, a typical daily dose may  
15   contain from about 25 mg to about 300 mg of the active ingredient. Duloxetine can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, bucal or intranasal routes. Alternatively, the compound may be administered by continuous infusion.

20           As used herein the term "patient" refers to a mammal, such as a mouse, guinea pig, rat, dog or human. It is understood that the preferred patient is a human.

          The term "treating" (or "treat") as used herein includes its generally accepted meaning which encompasses prohibiting, preventing, restraining, and slowing,  
25   stopping, or reversing progression of a resultant symptom. As such, the methods of this invention encompass both therapeutic and prophylactic administration.

          The compound of the present invention is preferably formulated prior to administration. Therefore, another aspect of the present invention is a pharmaceutical  
30   formulation comprising a compound of formula I, a pharmaceutically acceptable metabolically labile ester thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier, diluent, or excipient. The pharmaceutical

P-16031

-5-

formulations may be prepared by procedures using well-known by one of ordinary skill in the art. In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, and may be in the form of a capsule, sachet, paper, or other container.

5 When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active ingredient. The compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments containing, for example, up to 10% by weight of active compound, soft and hard gelatin capsules, 10 suppositories, sterile injectable solutions, and sterile packaged powders.

Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, 15 polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propyl hydroxybenzoates, talc, magnesium stearate, and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents. Compositions of the invention may be formulated so as to provide quick, sustained, or delayed release 20 of the active ingredient after administration to the patient by employing procedures well known in the art.

As used herein, the term "active ingredient refers to duloxetine.

25 The term "unit dosage form" refers to a physically discrete unit suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier, diluent, or excipient.

P-16031

-6-

The ability of duloxetine to treat gastrointestinal diseases according to this invention may be established according to clinical trial protocol of which the following is an example.

---

5

**Example 1**

This is a parallel, double-blind, placebo-controlled study of 465 patients who meet the Rome II criteria for Irritable Bowel Syndrome.

10

Patients who meet entry criteria at Visits 1 and 2 will continue in a 1 week drug-free period where they will complete their symptom diaries and then will be randomized to one of the following three treatment groups: duloxetine 60 mg QD, duloxetine 60 mg BID or placebo. Randomization will be performed in a 1:1:1 ratio.

15

Patients will be stratified into two groups: patients with a current major depressive disorder and patients without a current major depressive disorder. Following the screening phase, patients will be treated in a double-blind manner for 14 weeks two of which will be used for titration and tapering.

20

The efficacy of duloxetine 60 mg QD and duloxetine 60 mg BID compared with placebo on the reduction of pain severity during a 12-week, double-blind, therapy phase in patients who have irritable bowel syndrome (IBS), with or without major depression. Pain severity will be assessed by using average daily pain severity scores from the patient IBS study diary. Efficacy of duloxetine may also be shown via improvement of one or all of the following measures:

25

Improvement in average weekly patient quality of life score as measured by the IBS-SIS.

30

Improvement in the Clinical Global Impression of Severity (CGI)

Improvement in the Patient Global Impression of Improvement (PGI)

Improvement in the Brief Pain Inventory (BPI)

35

Improvement in the Daily Patient Diary (via symptom description)



P-16031

-7-

**Improvement in the Irritable Bowel Syndrome Symptoms Assessment  
Scale (IBS-SAS)**

**Improvement in the Bristol Stool Scale**

---

5

Improvement in symptoms of IBS via administration of duloxetine 60 mg QD and duloxetine 60 mg BID compared with placebo can be assessed via analysis of the results of implementation of this protocol in terms of discontinuation pattern, treatment-emergent adverse events, vital signs, electrocardiograms (ECG), and laboratory analysis.

10

Improvement in symptoms of IBS via administration of duloxetine 60 mg QD and duloxetine 60 mg BID compared with placebo can be assessed via analysis of the results of implementation of this protocol in terms of patient-reported outcomes as measured by the Medical Outcomes Study Short Form-36 (SF-36), the Quality of Life Depression Scale (QLDS), and the Sheehan Disability Scale (SDS).

15

P-16031

-8-

We Claim:

- 
1. Duloxetine, for use in the treatment of a disorder in a patient having a  
disorder, wherein the disorder is:
- 5            inflammatory bowel disorders (IBD),  
             functional bowel disorders (FBD),  
             dyspepsia,  
             crohn's disease,  
             ileitis,  
10            ischemic bowel disease,  
             ulcerative colitis,  
             irritable bowel syndrome, and  
             gastroesophageal reflux for FBD.
- 15           2.     A use of Claim 1 wherein the disorder is irritable bowel syndrome.
3.     The use of duloxetine for the manufacture of a medicament for treating  
a disorder in a patient wherein the disorder is as claimed in any one of claims 1 or 2.
- 20           4.     A pharmaceutical composition for treating a disorder in a patient,  
comprising duloxetine as the active ingredient, associated with ne or more  
pharmaceutically acceptable carriers, wherein the disorder is as claimed in any one of  
Claims 1 or 2.

P-16031

-9-

**ABSTRACT**

---

- 5        The present invention belongs to the fields of medicinal and pharmaceutical chemistry, and provides a new method of treating gastrointestinal disorders by the administration of duloxetine.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**